The MHRA’s reports on the COVID-19 vaccines, which are updated in line with its summary of the Yellow Card reporting publication. The MHRA Summary of Yellow Card Scheme Reporting for COVID-19 vaccines was published on March 8th 2023.
Since January, the reports have focused on the vaccines from the beginning of the Autumn 2022 booster campaign.
As of February 22nd 2023 in the U.K., 4,096 Yellow Card events were reported for the bivalent COVID-19 vaccine Pfizer/BioNTech, 5,108 for the bivalent COVID-19 vaccine Moderna, 57 for the COVID-19 vaccine Novavax and 2,319 were reported where the brand of the vaccine was not specified.
The MHRA had received 30 U.K. reports of suspected adverse drug reactions (ADRs) with a fatal outcome to the bivalent COVID-19 Pfizer/BioNTech vaccine and 42 fatal reports of suspected ADRs with the bivalent COVID-19 vaccine Moderna. The MHRA received no U.K. reports of a fatal outcome for the COVID-19 vaccine Novavax.
Interactive reports for each vaccine can be found here:
- COVID-19 Vaccine Pfizer/BioNTech monovalent
- COVID-19 Vaccine Pfizer/BioNTech bivalent
- COVID-19 Vaccine AstraZeneca
- COVID-19 Vaccine Moderna monovalent
- COVID-19 Vaccine Moderna bivalent
- COVID-19 Vaccine – brand unspecified or not in routine use in the U.K.
- COVID-19 Vaccine Novavax
It is not clear, though, why the reports focus on the ADRs since the booster campaign.
The full analysis reports substantially more data, with nearly half a million reports of suspected ADRs for the Covid vaccines and 2,546 suspected ADRs with a fatal outcome.